Fig. 2: Survival outcomes in cohort 4B in the safety analysis set. | Nature Medicine

Fig. 2: Survival outcomes in cohort 4B in the safety analysis set.

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Fig. 2: Survival outcomes in cohort 4B in the safety analysis set.

a, Kaplan-Meier curves of PFS in all patients. b, Kaplan-Meier curves of PFS by CLDN18.2 expression. c, Kaplan-Meier curves of PFS in patients with high CLDN18.2 expression by PD-L1 CPS. d, Kaplan-Meier curves of OS by CLDN18.2 expression. PFS was assessed by investigators per RECIST v1.1. PFS and OS were estimated using the Kaplan−Meier method with corresponding 95% CIs. One patient was missing a value for CLDN18.2 expression and is, therefore, excluded from b and d. Two patients were missing PD-L1 CPS values and are, therefore, excluded from c.

Back to article page